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PI3K/mTOR inhibitor GSK2126458
Alia Albawardi1, Muna Al Ayyan2, Mohamed Al Bashir3,4, Abdul-Kader Souid5 and Saeeda Almarzooqi1*Abstract
Background: Up-regulation of the PI3K/mTOR (phosphatidylinositol-3′ kinase/mammalian target of rapamycin)
signaling is common in carcinoma. Consistently, targeting these molecules has been shown to halt the growth of
many tumors. The main purpose of this study was to develop surrogate biomarkers of the antitumor activity of
PI3K/mTOR inhibitors.
Methods: Fragments from eight tumors were collected immediately after resection in ice-cold RPMI gassed with
95% O2 :5% CO2. Viability was determined by measuring tumor cellular respiration (mitochondrial O2 consumption).
The specimens were incubated at 37°C with and without 50 nM GSK2126458 (a highly potent and selective
inhibitor of PI3K/mTOR) for 90 min. The tissue was then processed for histology, measurement of intracellular
caspase-3 activity (using the caspase-3 substrate N-acetyl-asp-glu-val-asp-7-amino-4-methylcoumarin), and
immunohistochemical detection of the apoptotic biomarkers caspase-3, cytochrome C, and annexin A2.
Results: GSK2126458 induced morphologic changes in four tumors (two invasive ductal carcinomas, one invasive
lobular carcinoma, and one ovarian dysgerminoma), intracellular caspase-3 activity in three tumors (two invasive ductal
carcinomas and one poorly differentiated signet ring adenocarcinoma of gastric origin), and immunohistochemical
evidence of apoptosis in at least four tumors (three invasive ductal carcinomas and one adenocarcinoma of gastric
origin). Two tumors (ovarian serous carcinoma and moderately differentiated adenocarcinoma of colorectal origin)
demonstrated no treatment effect.
Conclusion: These preliminary results demonstrate the feasibility of using in vitro biomarkers for detecting antitumor
activities of the rapidly emerging PI3K/mTOR inhibitors.
Keywords: GSK2126458, PI3K, mTOR, Cytotoxicity, Caspases, Cellular respirationBackground
GSK2126458, a highly potent and selective inhibitor of
class I phosphoinositide 3-kinase (PI3K) and mammalian
target of rapamycin 1/2 complexes (mTOR) [1,2], is in
clinical trials for treatment of various solid tumors [3].
This agent targets the critical survival pathway PI3K/
PTEN/Akt/mTOR [4,5]. Inhibiting these signals has
been shown to promote apoptosis in tumor cells and im-
pair cellular bioenergetics (the biochemical processes
involved in energy biotransformation, such as oxidative
phosphorylation or cellular respiration) [6,7].
PI3K is activated by growth factor-stimulated receptor
tyrosine kinases, leading to downstream activation of* Correspondence: saeeda.almarzooqi@uaeu.ac.ae
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unless otherwise stated.Akt and mTOR with phosphorylation of key substrates
involved in preventing cell death [8]. These signals are
highly triggered in many cancer types; and mutations in
PI3K/AKT have been implicated in the pathogenesis of
several human carcinomas [9]. PI3K activating muta-
tions, for example, are frequently reported in breast can-
cer [10]. Consistently, inhibitors of PI3K possess potent
activities in these tumors [11]; and many of these drugs
are in clinical trials with promising results [12,13].
Recently an in vitro method suitable for performing
toxicological studies on thin slices of murine tissue was
described [14-17]. Adverse effects of agents were assessed
by histology and measurements of intracellular caspase
activity. A similar approach is employed here to assess
in vitro activities of GSK2126458 in tumors studied im-
mediately after resection. Morphologic and apoptoticral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological features of the studied tumors




Caspase-3 Cytochrome C Annexin A2
I - Invasive ductal carcinoma, NOS; grade 3; CS IIB; size 4.5 cm + + (↑15.7 fold) + (10%→ 20%) ¶ (2+→ 2+) ¶ (3+→ 2+)
- ER+, PR-, Her2-neu+, Ki-67 = 70%
- kc = 0.17 μM O2 min
-1 mg-1
- Age 73 yr; alive at 2 yr with lung and lymph nodes metastases
II
- Invasive ductal carcinoma, NOS, NH grade 2; CS IIB; size 4.5 cm - + (↑3.6 fold) + (1%→ 3%) + (2+→ 3+) ¶ (2+→ 2+)
- ER+, PR+, Her2-neu-, Ki-67 = 5%
- kc = 0.15 μM O2 min-1 mg-1
- Age 58 yr; free of disease at 18 months
III
- Invasive lobular carcinoma, NOS; NH grade 3; and lobular carcinoma
in situ (60% of the tumor mass; the studied component); CS IIIA; size 6.0 cm
+ - - (1%→ 1%) ¶ (3+→ 3+) ± (!) (2+→ 3+)
- ER+, PR+, Her2-neu-, Ki-67 = 30%
- kc = 0.22 μM O2 min-1 mg-1
- Age 62 yr; free of disease at 18 months
IV
- Invasive ductal carcinoma, NOS; NH grade 2; CS IIB; size 2.3 cm + - + (1%→ 2%) + (2+→ 3+) + (2+→ 3+)
- ER+, PR+, Her2-neu-, Ki-67 = 20%
- kc = 0.06 μM O2 min
-1 mg-1
- Age 41 yr; free of disease at 18 month
V
- Ovarian dysgerminoma; CS 1A; size 5.0 cm + nd - ǂ (3+→ ?) ǂ (2+→ ?)
- kc = nd
- Age 22 yr; free of disease at 18 months
VI
- Ovarian serous carcinoma; CS IIIB - - - (1%→ 1%) ¶ (3+→ 3+) ¶ (2+→ 2+)
- kc = nd
- Age 49 yr; free of disease at 12 months
VII
- Moderately differentiated adenocarcinoma, colorectal origin; CS IV - - - (5%→ 0%) - (1+→ 1+) (↑Necrosis) ¶ (2+→ 2+)
- kc = nd
- Age 60 yr; lost to follow-up
VIII
- Poorly differentiated signet ring adenocarcinoma of gastric origin, metastatic to the ovary; CS IV - + + (2%→ 4%) ¶ (3+→ 3+) + (2+→ 3+)
- kc = nd
- Age 66 yr; advanced disease on palliative care
NOS, Not otherwise specified; ER, Estrogen receptor; PR, Progesterone receptor; kc, rate of cellular respiration; CS, clinical stage; NH grade, Nottingham histological grade; nd, not done due to insufficient tumor sample;
¶, highly positive staining in treated and untreated specimens; !, inconsistent result (Additional file 2); ǂ, highly positive staining in untreated specimen (treated specimen was lost). Values in parentheses reflect
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GSK2126458 for 90 min [12]. These preliminary results
may stimulate further development of rapid in vitro as-
says for assessing sensitivity of tumors to PI3K/PTEN/
Akt/mTOR inhibitors.
Results
Clinicopathological features of the eight studied tumors
are listed in Table 1. The first tumor was invasive ductal
carcinoma of the breast (Nottingham histological grade 3).
It was positive for estrogen receptor (ER+), negative for
progesterone receptor (PR-), expressed human epidermal
growth factor receptor 2-neu (Her2-neu+), and had a
Ki-67 proliferation index of 70%. Histological features of
untreated tumor revealed pleomorphic neoplastic cells
arranged in cohesive nests and sheets with numerous
mitotic figures (Figure 1a-b). Treated tumor revealed
decreased cellular density and increased disintegration
of neoplastic cells with numerous apoptotic bodies
(Figure 1d-e). Expression of caspase-3 by immunopero-
xidase demonstrated 10% positivity in untreated tumor
(Figure 1c) and 20% positivity in treated tumor (Figure 1f).
Consistently, the AMC peak area (arbitrary unit, reflecting
capsease-3 activity) in untreated tumor was 460,886 and
in treated tumor was 7,234,911 (15.7-fold higher). TheFigure 1 Invasive ductal carcinoma. (a-f) Histology and expression of ca
sheets of cohesive neoplastic cells demonstrating apoptotic bodies (black a
(d-e) Treated tumor demonstrating loss of cellular cohesion and increased
(c) Untreated tumor demonstrating positivity (black arrow) for caspase-3 in
(f), immunoperoxidase (IP), 20×. (g) HPLC runs of intracellular caspase-3 ac
(retention time, ~12.8 min) in treated tumor was blocked by the pancaspas
by caspases. (h) Cellular respiration, measured on tumor arrival to the laboAMC peak area in treated tumor decreased to 1,523,682
(79% inhibition) in the presence of the pancaspase inhi-
bitor zVAD, confirming caspases were responsible for the
cleavage of Ac-DEVD-AMC (Figure 1 g). The tumor had
a cellular respiration rate of 0.17 μM O2 min
-1 mg-1
(Figure 1 h). Cytochrome C expression was similar in both
treated and untreated tumors, with a positive staining of
moderate intensity (2+) in >75% of neoplastic cells
(Additional file 1). Annexin A2 expression was 3+ in the
untreated tumor and 2+ in the treated tumor (Additional
file 2). Thus, this invasive ductal carcinoma demonstrated
treatment-associated morphologic and some apoptotic
changes (↑caspase-3 activity), Table 1.
The second tumor was another invasive ductal carcin-
oma of the breast (Nottingham histological grade 2). Its
hormonal status was ER+, PR+, and Her2-neu-; Ki-67
proliferation index was 5%. Histological features of the
treated and untreated specimens were similar (Figure 2
a-b vs. d-e). Expression of caspase-3 by immunoperoxi-
dase demonstrated positivity in 1% untreated tumor neo-
plastic cells (Figure 2c) and 3% positivity in treated
tumor (Figure 2f ). Intracellular caspase activity was
3.6-fold higher in the treated tumor (Figure 2 g-h). Cyto-
chrome C expression was more prominent in the treated
specimen demonstrating an intensity of 3+ in >75% ofspase-3 by immunoperoxidase. (a-b) Untreated tumor demonstrating
rrow) and mitotic figures (red arrow), H&E at 20× and 40×, respectively.
apoptotic bodies (black arrow), H&E at 20× and 40×, respectively.
up to 10% of neoplastic cells compared to 20% in treated tumor
tivity in treated and untreated tumor specimens. The AMC peak
e inhibitor zVAD, confirming cleavage of Ac-DEVD-AMC was mediated
ratory to affirm viability.
Figure 2 Breast invasive ductal carcinoma. (a-f) Histology and expression of caspase-3 by immunoperoxidase. (a-b) Untreated tumor demonstrating
rare islands of cohesive neoplastic cells (black arrow), H&E at 20× and 40×, respectively. (d-e) Treated tumor demonstrating numerous islands and
cords of neoplastic cells with a preserved cellular cohesion (black arrow), H&E at 20× and 40×, respectively. (c) Untreated tumor demonstrating rare
residual neoplastic cells (black arrow) with rare staining for caspase-3 in ~1% of neoplastic cells compared to ~3% in treated tumor (f), immunoperoxidase
(IP), 40×. (g-h) HPLC runs of intracellular caspase-3 activity in treated and untreated tumor. The AMC peak (retention time, ~4.4 min) in treated tumor
was blocked by the pancaspase inhibitor zVAD, confirming the cleavage of Ac-DEVD-AMC was mediated by caspases. (i) Cellular respiration, measured
immediately on tumor arrival to the laboratory to affirm viability.
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that demonstrated a 2+ intensity of staining in 26-75%
of neoplastic cells (Additional file 1). Annexin A2 ex-
pression was 2+ in both specimens (Additional file 2).
The cellular respiration rate was 0.15 μM O2 min
-1 mg-1
(Figure 2i). Thus, only treatment-associated apoptotic
changes were evident in this tumor.
The third case was an invasive lobular carcinoma of
breast (Nottingham histological grade 3). The tumor was
ER+, PR+, and Her2-neu-; the Ki-67 proliferation index
was 30%. The invasive tumor was associated with an in-
situ component that represented about 60% of the
tumor. Representative samples of tumor used in this
study demonstrated predominantly the in situ carcin-
oma. Untreated tumor showed cells mostly confined to
distended lobular acini by a solid proliferation of rela-
tively uniform poorly cohesive cells. Many of the cells
contained small intracytoplasmic vacuoles (Figure 3a-b).
Treated tumor demonstrated a decrease in the density
of cells with increased cellular dyscohesion and frag-
mentation of cytoplasm and many degenerative nuclei
(Figure 3d-e). Expression of caspase-3 demonstrated 1%
positivity in both the treated and untreated tumor
(Figure 3c and f). Intracellular caspase activity was alsosimilar in both specimens (Figure 3 g). Cytochrome C
(3+ in > 75% of in situ neoplastic cells) was highly
expressed in treated and untreated specimens. Annexin
A2 was positive in both treated and untreated samples,
but showed a higher intensity in treated tumor (2+ in
treated tumor compared to 1+ in untreated tumor),
Additional files 1 and 2. Cellular respiration rate was
0.22 μM O2 min
-1 mg-1 (Figure 3 h). Thus, only treat-
ment-associated morphologic changes were evident in this
tumor.
The fourth tumor was invasive ductal carcinoma of the
breast (Nottingham histological grade 2). The hormonal
status was ER+, PR+, Her2-neu-; the Ki-67 proliferation
index was 20%. Histological features of the untreated
tumor showed neoplastic cells arranged in cords and
nests with moderate nuclear pleomorphism, amphophilic
cytoplasm, vesicular nuclei, inconspicuous nucleoli, and
a background of desmoplastic reaction (Figure 4a-b).
Treated tumor revealed decreased cellular density with
dyscohesion and numerous apoptotic bodies, suggesting
a morphologic response (Figure 4d-e). Expression of
caspase-3 demonstrated 1% positivity in untreated tumor
(Figure 4c) and 2% positivity in treated tumor (Figure 4f).
Caspase activity was about the same in treated and
Figure 3 Breast lobular carcinoma in situ. (a-f) Histology and expression of caspase-3 by immunoperoxidase. (a-b) Untreated tumor demonstrating
expanded acini by an in situ proliferation of uniform neoplastic cells, H&E at 10× and 40×, respectively. (d-e) Treated in situ carcinoma demonstrating
fragmentation and degeneration of neoplastic cells (black arrow), H&E at 10× and 40×, respectively. (c and f) Untreated and treated tumor showed rare
positivity (1%, black arrow) for caspase-3, immunoperoxidase (IP), 40×. (g) HPLC runs of intracellular caspase-3 activity in treated and untreated tumor.
The AMC peak (retention time, ~4.8 min) in treated tumor was blocked by zVAD. (h) Cellular respiration, measured immediately on tumor arrival to the
laboratory to affirm viability.
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tive in both treated and untreated tumor with a moderate
intensity; but it was positive in >75% (3+) of cells in
treated tumor compared to 26-75% (2+) of cells in the un-
treated tumor. Annexin A2 expressions was increased in
intensity in the treated specimen (3+) compared to the
untreated specimen (2+), Additional files 1 and 2. The cel-
lular respiration rate was 0.06 μMO2 min
-1 mg-1 (Figure 4
h). Thus, this tumor demonstrated treatment-associated
morphologic and apoptotic changes.
The fifth tumor was ovarian dysgerminoma. Histological
features of the untreated tumor revealed nests of neo-
plastic cells separated by fibrous bands rich in lympho-
plasmacytic infiltrate. Neoplastic cells were characterized
by uniformly round central nuclei, clear-to-eosinophilic
cytoplasm, and prominent single nucleoli. Mitotic figures
were abundant (Figure 5a-b). Treated tumor revealed de-
creased cellular density with cytoplasmic disintegration,
vacuolar degeneration, nuclear basophilia, pyknotic nuclei,
and numerous apoptotic bodies (Figure 5d-e). Expression
of caspase-3 in untreated tumor demonstrated positivity
in lymphocytes and some of neoplastic cells (Figure 5c). In
treated tumor, there was positivity in residual lymphocytes
and lack of positivity in disintegrating pyknotic neoplastic
cells (Figure 5f). Assessment of cytochrome C andannexin A2 expression in the untreated tumor was not
feasible due to loss of tissue. Thus, this tumor demon-
strated only treatment-associated morphologic changes.
The sixth tumor was high-grade serous ovarian carcin-
oma. The untreated tumor consisted of neoplastic cells
arranged in papillary folds, slit like fenestrations and com-
plex glands. The cells showed marked nuclear atypia and
pleomorphism with frequent mitoses. There was extensive
tumor associated necrosis (Figure 6a-b). Treated tumor
demonstrated similar histology, but less pronounced foci
of necrosis (Figure 6d-e). Expression of caspase-3 by
immunoperoxidase demonstrated 1% positivity in both
treated and untreated specimens (Figure 6c and f). Cyto-
chrome C expression was highly positive (3+ in >75% of
neoplastic cells) in both specimens (Additional file 1).
Annexin A2 expression was also the same in both speci-
mens (Additional file 2). Consistently, the AMC peak areas
for treated and untreated samples were about the same
(Figure 6 g-h). Thus, this serous ovarian carcinoma demon-
strated no treatment-associated changes.
The seventh tumor was metastatic colorectal carcinoma.
Histological examination revealed predominantly necrotic
tumor with shadows of neoplastic cells in both treated
and untreated samples (Figure 7a-b, d-e). Expression
of caspase-3 by immunoperoxidase demonstrated 5%
Figure 4 Invasive ductal carcinoma. (a-f) Histology and expression of caspase-3 by immunoperoxidase. (a-b) Untreated tumor cords and nests
of neoplastic cells in a background of desmoplastic reaction, H&E at 10× and 40×, respectively. (d-e) Treated tumor demonstrating decreased
cellularity, cellular dyscohesion and numerous apoptotic bodies (black arrow), H&E at 10× and 40×, respectively. (c and f) demonstrating rare
expression by caspase-3 in untreated tumor ( 1%) compared to up to 2% in treated tumor, immunoperoxidase (IP), 40×. (g) HPLC runs of intracellular
caspase-3 activity in treated and untreated tumor (AMC peak retention time, ~4.8 min). (h) Cellular respiration, measured immediately on tumor arrival
to the laboratory to affirm viability.
Figure 5 Ovarian dysgerminoma. (a-f) Histology and expression of caspase-3 by immunoperoxidase in treated and untreated tumor specimens.
(a-b) untreated tumor demonstrated nests of neoplastic cells separated by fibrous bands rich in lympho-plasmacytic infiltrate. Mitotic figures are
numerous (red arrow), H&E, 10× and 40×, respectively. (d-e) Treated tumor revealing decreased cellular density with cytoplasmic disintegration,
vacuolar degeneration, nuclear basophilia, pyknotic nuclei, and numerous apoptotic bodies (black arrow), H&E, 10× and 40×, respectively.
(c and f) Expression of caspase-3 in untreated tumor is seen in lymphocytes (black arrow) and some of neoplastic cells. In the treated tumor,
there is positivity in residual lymphocytes and lack of positivity in disintegrating pyknotic neoplastic cells, immunoperoxidase (IP), 40×.
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Figure 6 Ovarian serous carcinoma. (a-f) Histology and expression of caspase-3 by immunoperoxidase in treated and untreated tumor specimens.
(a-b and c-d) There is preserved tumor histology in the treated tumor compared to untreated tumor, H&E, 10 and 40×. (c and f) stained similar in
both tumors with a low level of expression, immunoperoxidase (IP, 40×). (g-h) HPLC runs of intracellular caspase-3 activity in treated and untreated
tumor (AMC peak retention time, ~4.8 min).
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in treated tumor (Figure 7f). The AMC peak area did not
increase in treated tumor (Figure 7 g-h). Cytochrome ex-
pression was negative (1+ in <5%) in both specimens with
prominent tumor necrosis (Additional file 1). Annexin A2
expression was highly positive (2+) in both treated and
untreated specimens (Additional file 2). Thus, assessment
of drug effects in this tumor was not feasible as both sam-
ples were predominantly necrotic.
The eighth tumor was a metastatic poorly differentiated
adenocarcinoma of gastric origin. Both untreated and
treated specimens revealed clusters of neoplastic cells with
signet-ring cell morphology. Cytoplasmic and nuclear de-
tails were preserved in both samples (Figure 8a-b, d-e).
Expression of caspase-3 by immunoperoxidase demon-
strated 2% positivity in untreated tumor (Figure 8c) and
4% positivity in treated tumor (Figure 8f). AMC peak area
(calculated as area without zVAD minus area with zVAD)
in untreated tumor was less than zero and in trea-
ted tumor was 1,727,817 (Figure 8 g-h). Cytochrome C
was positive in both specimens (>75% of cells, or 3+)
(Additional file 1). Annexin A2 expression increased in the
treated specimen (Additional file 2). Thus, the GSK2126458
treatment was associated with mild increases in caspase-3
expression and activity.Discussion
This study described structural and apoptotic biomarkers
associated with exposure of eight relatively viable tumors
to the PI3K/mTOR inhibitor GSK2126458. Morphologic
changes were observed in four tumors and apoptotic
changes in four tumors (Table 1).
Intracellular caspase-3 was assessed by immunope-
roxidase staining and by the synthetic cell-permeable
caspase-3 substrate Ac-DEVD-AMC. Other utilized apop-
totic biomarkers were immunoperoxidase staining for
cytochrome C and annexin A2. It is expected that tumor
resection will lead to induction of apoptosis with caspase
activation. Nevertheless, the GSK2126458 treatment fur-
ther intensified caspase-3 induction in three tumors
(Table 1). This observation is consistent with the recent
finding of rapid induction of apoptosis by PI3K inhibitors
[18]. It also suggests the suitability of using apoptotic bio-
markers to monitor PI3K/mTOR therapeutic activities. It
is worth noting, however, that an accurate assessment of
the drug effect requires several structural and functional
biomarkers (e.g., drug-induced changes in histology, gene
expression, caspase induction, and cellular bioenergetics),
preferably performed on multiple tumor fragments. It is
also imperative to note that in vitro observations may not
necessarily correlate with patient response to therapy.
Figure 7 Metastatic colorectal adenocarcinoma. (a-f) Histology and expression of caspase-3 by immunoperoxidase. (a-b and c-d) Sample
consisted of necrotic neoplastic tissue, H&E, 10× and 40×, respectively. (c and f) Caspase-3 demonstrated a positive staining (black arrow) in up
to 5% of necrotic neoplastic cells in untreated tissue and absence of staining in treated tissue, immunoperoxidase (IP), 40×. (g-h) HPLC runs of
intracellular caspase-3 activity in treated and untreated tumor (AMC peak retention time, ~4.8 min).
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the behavior of a fragment may not necessarily represent
the entire cell population. This obstacle was somewhat
minimized in this study by having the experienced histo-
pathologists sampling multiple areas from each tumor.
For example, the majority of Tumor #3 was in-situ car-
cinoma, with a little invasive lobular carcinoma. This in-
situ component probably has less molecular alterations
and probably less proliferative potential than the invasive
carcinoma. This sampling problem may have reduced
caspase activation in the studied tumor component
(Figure 3 and Table 1). In tumor # 2, the tissue consisted
mostly of fibrous tumor stroma with little neoplastic
nests (Figure 2). This artifact hindered adequate assess-
ment of morphologic changes following drug treatment.
The GSK2126458 treatment induced cytotoxicities in
the four studied breast tumors (Tumors 1-4). This
preliminarily observation supports the role of PI3K in
breast carcinogenesis and the potential therapeutic
utility of PI3K/mTOR inhibitors in invasive ductal carci-
nomas [10-13]. The ovarian serous carcinoma (Tumor #6)
and adenocarcinomas of colorectal origin (Tumor #7)
had high background levels of necrosis and apoptosis;these features hindered an accurate assessment of the
treatment-induce changes.
Data on the role of PI3K pathway in ovarian dysgermi-
noma are limited (Tumor #5). Thus, the observed mor-
phologic changes following GSK2126458 treatment are
encouraging and warrant follow-up studies (Figure 5).
Unfortunately, we were unable to complete the apoptotic
studies in this tumor since the specimen was inadequate
(Table 1).
The limitations to this study are recognized. First, the
sampled tissue might consist only of necrotic tumor which
will affect the study results. This was seen in tumor #7
which consisted predominantly of necrotic tissue. As colo-
rectal carcinoma is known to have large areas of necrotic
tissue this explains the presence of necrotic tissue only in
the study sample. Necrosis of tumor can be expected if
there is a delay in the transportation of tumor after resec-
tion from the operating room to the laboratory. Meticu-
lous coordination between the surgeons and pathologists
to maintain tumor viability is crucial. Second, the speci-
mens from four tumors were insufficient for performing
all planned assessments (Tumors #5-8). Third, there is the
issue of tumor heterogeneity, which can affect the results.
Figure 8 Metastatic poorly differentiated adenocarcinoma. (a-f) Histology and expression of caspase-3 by immunoperoxidase. (a-b and c-d)
Treated and untreated tumors show similar morphological changes, H&E, 10× and 40×, respectively. (c and f) Caspase-3 demonstrates a mildly
increased staining (black arrow) in treated tumor (4%) compared to (2%) in untreated tumor, immunoperoxidase ( IP), 40×. (g-h) HPLC runs of
intracellular caspase-3 activity in treated and untreated tumor (AMC peak retention time, ~4.8 min).
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areas in addition to use of multiple samples for each
condition facilitates reducing this limitation. Fourth, the
assessments were based on single measurements; this in-
adequacy halted statistical or correlation analyses. Fifth,
the study did not include biomarkers for angiogenesis
[19] or for blocking PI3K downstream molecules. The de-
scribed method in current study may not be appropriate
for assessing angiogenesis in a given tumor due to the
short drug exposure time. Expression of angiogenesis
molecules, however, is worth assessing in future studies
using this methodology. Sixth, the clinical significance of
employed descriptive biomarkers (morphologic and apop-
totic changes) remains unclear. These challenges are rea-
sonable goals to overcome in follow-up studies.Conclusion
Morphologic derangements and apoptotic intensifications
were observed in a few tumors following in vitro treat-
ment with GSK2126458 (50 nM for 90 min; e.g., Tumor
#1, invasive ductal carcinoma). These preliminarily results
confirm that some tumors are highly dependent on thePI3K/mTOR signaling. Further studies are needed to as-
sess the clinical significance of these in vitro observations.
Methods
Reagents
The PI3K/mTOR inhibitor GSK2126458 (m.w. = 505.5, cat.
S2658) was purchased from Selleck Chemicals (Houston,
TX). The oxygen probe Pd(II) complex of meso-tetra-
(4-sulfonatophenyl)-tetrabenzoporphyrin (Pd phosphor)
was purchased from Porphyrin Products (Logan, UT). A
lyophilized powder of caspase inhibitor I [N-benzyloxy-
carbonyl-val-ala-asp(O-methyl)-fluoromethylketone; zVAD;
m.w = 467.5; pancaspase inhibitor] was purchased from
Calbiochem (La Jolla, CA). The caspase-3 substrate Ac-
DEVD-AMC (N-acetyl-asp-glu-val-asp-7-amino-4-methyl-
coumarin; m.w. = 675.64; caspase-3 substrate) was
purchased from Axxora LLC (San Diego, CA). Rabbit
anti-cleaved caspase-3 antibody and rabbit anti-annexin
A2 antibody (#D11G2) were purchased from Cell Signaling
Technology (Boston, MA, USA). Rabbit anti-cytochrome c
antibody [(H-104): sc-7159] was purchased from Santa
Cruz Biotechnology, Inc. (Texas, USA). RPMI medium
1640 was purchased from Sigma-Aldrich (St. Louis, MO).
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DEVD-AMC (7.4 mM) were reconstituted in dimethyl
sulfoxide and stored at -20°C. Pd phosphor (2.5 mg/ml =
2 mM) was reconstituted in dH2O and stored in small
aliquots at -20°C.
Tumors
The ethical approval of this study was obtained from
Tawam Institutional Review Board and Al Ain Medical Dis-
trict Human Research Ethics Committee (Protocol 11/45).
Informed consent was obtained from each patient. Eight
tumors were studied (Table 1). The specimens (typically,
0.5×0.5×0.5 cm) were collected immediately following
tumor resection, immersed in ice-cold RPMI medium
(gassed with 95% O2:5% CO2), and cut into ~30-mg frag-
ments. Tumor viability was assessed on sample arrival to
the laboratory by measuring cellular respiration (cellular
mitochondrial O2 consumption) as previously described
and discussed briefly below [14-17]. Viable tumors were in-
cubated at 37°C in 10 mL RPMI (continuously gassed with
95% O2:5% CO2) with and without 50 nM GSK2126458
for 90 min (150 min for tumor #5). At the end of the incu-
bation period, the fragments were processed for histology,
expression of caspase-3 by immunoperoxidase, and deter-
mining intracellular caspase activity using the caspase-3
substrate Ac-DEVD-AMC as previously described and dis-
cussed briefly below [14-17].
Histology
Three micron-thick sections of formalin-fixed, paraffin-
embedded tumor tissue were obtained and stained with
hematoxylin and eosin (H&E). Positivity for ER, PR,
Her2-neu, and Ki-67 was assessed based on clinically
utilized guidelines on breast biomarker reporting pub-
lished by the College of American Pathologist [20].
Immunohistochemistry
Immunohistochemical detections of caspase-3, cyto-
chrome c, and annexin A2 were performed as previously
described [16]. Caspase-3 was expressed as a percentage
of tumor cells showing positive nuclear immunostaining.
For cytochrome c a dilution of 1:500 was used and for
annexin A dilution of 1:200 was used. The immunostain-
ing intensity of cytochrome c was scored using a semi-
quantitative manual method. The intensity of staining was
scored as: strong (3+), moderate (2+), weak (1+), and
negative (0).In addition, the percentage of positive cells
was also scored using following: <5% of cells (0), 5–25%
(1), 26–75% (2), and >75% (3) of cells. A tumor was
regarded as positive if >5% of tumor cells showed immu-
nostaining. A tumor was classified as negative if there was
complete absence of immunostaining in tumor cells or if
<5% of tumor cells showed positive immunoreactivity
[21]. Annexin A2 immunostaining intensity was scoredusing a semi-quantitative manual method: strong (3+),
moderate (2+), weak (1+), and negative (0). The staining
pattern was cytoplasmic plus membranous. A positive
tumor response to the GSK2126458 treatment was set as
at least one scale level increase in the immunostaining in-
tensity [16].Caspase activity
Tissue fragments were incubated at 37°C in 1.0 mL RPMI
gassed with 95% O2:5% CO2 with and without 32 μM the
pancaspase inhibitor zVAD-fmk for 10 min. The caspase-
3 substrate Ac-DEVD-AMC (37 μM) was then added and
the incubations continued for 20 min. The fragments were
disrupted by vigorous homogenization and 10 passages
through a 27-G needle. The supernatants were collected
by centrifugation (~16,300 g for 90 min) through a Micro-
centrifuge Filter (nominal m.w. limit = 10,000 Dalton,
Sigma©), separated on HPLC, and analyzed for the free
fluorogenic AMC moiety as previously described [14-17].
For tumor #1, the HPLC running solvents were 1:3
CH3CN:H2O and dH2O (1:1 isocratic). For remaining
measured tumors, the running solvents were CH3OH and
dH2O (1:1 isocratic).Oxygen measurement
Phosphorescence O2 analyzer was used to monitor tumor
O2 consumption at 37°C as previously described [14-17].
Cellular respiration was measured to assess viability of
Tumors #1-4 (zero-order kinetics of cellular mitochon-
drial O2 consumption confirms a viable tumor). Briefly, a
tumor fragment was placed in 1-mL sealed glass vial and
placed in the instrument. O2 concentration was monitored
as a function of time with the aid of the oxygen probe Pd
(II) complex of meso-tetra-(4-sulfonatophenyl)-tetraben-
zoporphyrin. O2 concentration decreased linearly with
time, indicating the kinetics of mitochondrial O2 con-
sumption was zero-order. The rate of respiration (k, μM
O2 min
-1) was the negative of the slope d [O2]/dt. The
value of k was divided by specimen weight (kc, μM
O2 min
-1 mg-1).Additional files
Additional file 1: Immunohistochemical detection of cytochrome C
in the studied tumors. The immunostaining intensity was scored
manually: strong (3+), moderate (2+), weak (1+), and negative (0). The
following scale was used: <5% of cells (0), 5–25% (1), 26–75% (2),
and >75% (3) of cells. A tumor was regarded as positive if >5% of tumor
cells showed immunostaining. A tumor was classified as negative if
there was complete absence of immunostaining in tumor cells or if <5%
of tumor cells showed positive immunoreactivity as previously
described [22].
Additional file 2: Immunohistochemical detection of annexin A2 in
the studied tumors. The staining pattern is cytoplasmic +membranous.
Two antibody dilutions were used (1:200 and 1:400). The immunostaining
Albawardi et al. Cancer Cell International 2014, 14:90 Page 11 of 11
http://www.cancerci.com/content/14/1/90intensity was scored using a semi-quantitative manual method: strong
(3+), moderate (2+), weak (1+), and negative (0).
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